Expert Consensus on Application of Chinese Patent Medicine of COVID-19 Omicron Mutant
- Article number:
- 2096-1340(2022)06-0001-07
- Keywords:
- COVID-19; Omikjon; Chinese medicine; Chinese patent medicine; Expert consensus
- ZTFLH:
- R286
- Code:
- A
- Abstract:
- Since the outbreak of COVID-19 in 2020，Chinese medicine has achieved remarkable treatment results，played an important role in the global epidemic prevention and control，and was highly recognized by WHO.In November 2021，the COVID-19 Omicron mutant appeared for the first time and spread rapidly.Jilin and Shanghai in China successively broke out and spread throughout the country.In order to more effectively respond to the infection of Omikron’s variant strain，the World Federation of Chinese Medical Societies Emergency Committee，the First Aid Group of Integrated Traditional Chinese and Western Medicine of the Emergency Branch of the Chinese Medical Association，the First Aid Group of Integrated Traditional Chinese and Western Medicine of the Emergency Branch of the Emergency Physician Branch of the Chinese Medical Association，the Emergency Branch of the Shanghai Chinese Medical Association，the Institute of Emergency and Critical Care of the Shanghai University of Traditional Chinese Medicine and other academic institutions have organized first-line treatment experts for Omikron’s COVID-19 variant strain.The clinical symptoms of patients in Jilin and other areas infected with Omikron were investigated and discussed on issues related to the application of Chinese patent medicine in combination with the National Diagnosis and Treatment Plan forCOVID-19 (Trial Version 9)，and a consensus was formed，with a view to playing a clinical guiding role in the prevention and control of the current infection of Omikron variant of COVID-19 and the future epidemic situation.
References:
［1］中国国家卫生健康委员会.新型冠状病毒肺炎诊疗方案（试行第九版）［J］.国际流行病学传染病学杂志，2022，49（2）：73-80.
［2］方邦江，苏红，赵软金，等.新型冠状病毒奥密克戎变异株感染中医药防治专家共识［J］.中国急救医学，2022，42（4）：277-280.
［3］徐湘茹，孙鼎，曹敏，等.上海市4264例无症状及轻型新冠病毒感染者临床特征及预后转归分析［J］.中华危重病急救医学，2022，34（5）：449-453.
［4］方邦江，邬鑫鑫，张文，等.基于中医疫病理论之“表里双解”截断扭转法治疗新冠肺炎的理论与实践［J］.陕西中医药大学学报，2022，45（4）：1-6.
［5］方邦江，齐文升，杨志旭，等.《新型冠状病毒肺炎诊疗方案（试行第九版）》中医治疗更新及其对奥密克戎变异株感染防治指导作用［J］.陕西中医药大学学报，2022，45（3）：1-4.
［6］方邦江，齐文升，黄烨.新型冠状病毒感染的肺炎中西医结合防控手册［M］.北京：人民卫生出版社，2020.
［7］陈晓蓉，方邦江.中西医结合诊疗新型冠状病毒肺炎验案120例［M］.上海：上海科学技术出版社，2020.
［8］苗青,史利卿,封继宏,农英.中成药防治新型冠状病毒肺炎专家共识［J/OL］.中国中西医结合杂志:1-4［2022-09-26］.http://kns.cnki.net/kcms/detail/11.2787.R.20220301.1533.004.html
［9］北京中医药学会临床合理用药评价专业委员会，首都医科大学附属北京世纪坛医院临床合理用药生物特征谱学评价北京重点实验室.新型冠状病毒肺炎早期中成药干预的药学共识(北京)［J］.中国医院药学杂志，2020，40（8）：837-846.
［10］方邦江，张文，周爽，等.基于“急性虚证”理论防治新型冠状病毒肺炎探析［J］.中医杂志，2021，62（9）：826-828.
［11］上海市新型冠状病毒感染中医药诊疗专家共识（2022春季版）［J］.上海中医药杂志，2022，56（7）：5-6.
［12］田琳，王檀，王子元，等.2108例新型冠状病毒奥密克戎变异株感染患者的中医证候特征及诊疗策略探析［J］.中华中医药学刊，2022，40（5）：17-20.
Memo
国家中医药管理局2022年第五批新型冠状病毒感染肺炎中医药应急专项课题（2022ZYLCYJ05-4）；上海中医药大学2022年度应对奥密克戎感染新型冠状病毒肺炎应急攻关项目（2022YJ-03,2022YJ-06）